Immune cell therapy shows promise for tough lupus cases
NCT ID NCT06189157
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This early-stage trial tests a treatment called MB-CART19.1, which uses a patient's own immune cells modified to target and destroy faulty B cells that drive lupus. It enrolls 29 adults with severe lupus that hasn't responded to standard therapies. The goal is to find a safe dose and see if it can induce remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Otto-von-Guericke-Universität Magdeburg
RECRUITINGMagdeburg, Germany
Contact
Contact
-
Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II
RECRUITINGTübingen, Germany
Contact
Contact
-
Universitätsklinikum Erlangen, Medizinische Klinik 3
NOT_YET_RECRUITINGErlangen, Germany
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MB-CART19.1 (a type of CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could offer a new treatment option that puts severe lupus into remission, reducing the need for lifelong medications.
What could go wrong
This is an early phase 1/2 trial with only 29 participants, so results may not apply broadly. CAR T-cell therapy carries risks like cytokine release syndrome and nervous system side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.